{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:01:39Z","timestamp":1780786899086,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacl.2026.03.018","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:59:37Z","timestamp":1774583977000},"page":"1078-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying severe hypercholesterolemia in participants of ASCVD trials: Implications for trial conduct and opportunistic screening"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-7765","authenticated-orcid":false,"given":"Abhayjit","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie St.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Laffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Skoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Bruemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-6464","authenticated-orcid":false,"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1649-2110","authenticated-orcid":false,"given":"Ashish","family":"Sarraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jacl.2026.03.018_bib1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.03.018_bib2","series-title":"FDA Guidance for Industry: Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.jacl.2026.03.018_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond","volume":"19","author":"Safarova","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.018_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1740774515625964","article-title":"Key cost drivers of pharmaceutical clinical trials in the United States","volume":"13","author":"Sertkaya","year":"2016","journal-title":"Clin Trials"},{"issue":"8","key":"10.1016\/j.jacl.2026.03.018_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5551\/jat.CR003","article-title":"Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017","volume":"25","author":"Harada-Shiba","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"20","key":"10.1016\/j.jacl.2026.03.018_bib6","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: a systematic review and meta-analysis","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.03.018_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.018_bib8","first-page":"16143","article-title":"A novel clinical prediction model for familial hypercholesterolemia: implementation of a statin-correction calculator to enhance diagnostic yield","volume":"142","author":"Kanji","year":"2020","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jacl.2026.03.018_bib9","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.018_bib10","first-page":"172","article-title":"Severe heterozygous familial hypercholesterolaemia and risk for cardiovascular disease: a study of a cohort of 14 000 mutation carriers","volume":"234","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.03.018_bib11","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacl.2026.03.018_bib12","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.018_bib13","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.jacl.2026.03.018_bib14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in participants with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.03.018_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100393","article-title":"The burden of severe hypercholesterolemia and familial hypercholesterolemia in a population-based setting in the US","volume":"12","author":"Saadatagah","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.03.018_bib16","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and participants with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jacl.2026.03.018_bib17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.018_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.123.064566","article-title":"Long-term mortality in patients with severe hypercholesterolemia phenotype from a racial and ethnically diverse US cohort","volume":"149","author":"Miles","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.03.018_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41746-019-0101-5","article-title":"Finding missed cases of familial hypercholesterolemia in health systems using machine learning","volume":"2","author":"Banda","year":"2019","journal-title":"NPJ Digit Med"},{"issue":"7","key":"10.1016\/j.jacl.2026.03.018_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2019.1518","article-title":"Identifying familial hypercholesterolemia using a blood donor screening program with more than 1 million volunteer donors","volume":"4","author":"Jackson","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.018_bib21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jacl.2023.01.006","article-title":"The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of familial hypercholesterolaemia","volume":"17","author":"Thayabaran","year":"2023","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:44:54Z","timestamp":1780785894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1933287426000905"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.018","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying severe hypercholesterolemia in participants of ASCVD trials: Implications for trial conduct and opportunistic screening","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}